Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 17/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.56 |
| ▸ | MEN1 | O00255 | 12/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 12/20 | 0.56 |
| ▸ | POLB | P06746 | 4/20 | 0.56 |
| ▸ | BLM | P54132 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | RECQL | P46063 | 3/20 | 0.55 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | ERN1 | O75460 | 1/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 5/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12416911 | 0.91 | MAPT (0.54) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL12416870 | 0.87 | ALDH1A1 (0.55) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL12417045 | 0.83 | ERN1 (0.61) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL12416896 | 0.83 | MAPT (0.65) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL12417020 | 0.82 | ALDH1A1 (0.53) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL12416994 | 0.82 | MAPT (0.53) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL12416895 | 0.81 | MAPT (0.72) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL12417088 | 0.81 | MAPT (0.71) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL12416990 | 0.80 | MAPT (0.61) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL12417015 | 0.79 | MAPT (0.57) | MAPTALDH1A1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-07-14 | — | — | US | disclosed |
| US-7915245-B2 | Using small molecules as binding ligands, for the recruitment of Fas-associated death domain protein, activation of death-inducing signaling complex, caspase-8, and apoptosis in malignant cells; anticarcinogens, antitumor agents; enhanced cellular differentiation, minimizing cytolysis to healthy cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-03-29 | — | — | US | disclosed |
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | BID, BAD, MCL1 | MAPT 3638/4885ALDH1A1 3768/4885MEN1 392/4885 |
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | BID, BAD, MCL1 | MAPT 3638/4885ALDH1A1 3768/4885MEN1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.